103
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin

, , , , , & show all
Pages 41-45 | Published online: 15 Jan 2010

References

  • GigliottiFWilliamsWTHaydenFGHendleyJOBenjaminJDickensMEtiology of acute conjunctivitis in childrenJ Pediatr19819845315366970802
  • WeissABrinserJHNazar-StewartVAcute conjunctivitis in childhoodJ Pediatr1993122110148419593
  • RosePWHarndenABrueggemannABPereraRSheikhACrookDChloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trialLancet2005669479374315993231
  • LichtensteinSJDorfmanMKennedyRStromanDControlling contagious bacterial conjunctivitisJ Pediatr Ophthalmol Strabismus2006431192616491721
  • GranetDBDorfmanMStromanDCockrumPA multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitisJ Pediatr Ophthalmol Strabismus200845634034919043945
  • LichtensteinSJWagnerRSJamisonTBellBStromanDWSpeed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studiesAdv Ther20072451098111118029337
  • NorrbySREmerging antibiotic resistance in gram positive bacteria: return to the preantibiotic era?Hong Kong Med J19951129135
  • AndersonRJKimbroughRLennonKAdverse drug reactions: ocular sensitivity reaction to neomycinJ Pharm Pract199692vvii
  • Ophthalmic moxifloxacin (vigamox) and gatifloxacin (zymar)The Medical Letter20044611792527
  • AldridgeKEAshcraftDSComparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobesAntimicrob Agents Chemother19974137097119056020
  • WoodcockJMAndrewsJMBoswellFJBrenwaldNPWiseRIn vitro activity of BAY 12–8039, a new fluoroquinoloneAntimicrob Agents Chemother19974111011068980763
  • Alcon Laboratories Inc. Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5%. [Package insert] 2008.
  • OgawaGSHyndiukRAThe fluoroquinolones: new antibiotics in ophthalmologyInt Ophthalmol Clin199333459688258498
  • DrlicaKMechanism of fluoroquinolone actionCurr Opin Microbiol19992550450810508721
  • AsbellPAColbyKADengSMcDonnellPMeislerDMRaizmanMBOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
  • KowalskiRPYatesKARomanowskiEGKarenchakLMMahFSGordonYJAn ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration dataOphthalmology200511211198716183128
  • SmithAFWaycasterCThe annual cost of bacterial conjunctivitis in the United States: Evidence from an economic modeling approach13th Annual ISPOR Meeting2008May 3–7Toronto, CanadaValue in Health 2008113A291
  • Pupil Accounting. San Diego Unified School District. Available from: http://www.sandi.net/pupil_acct/ Accessed November 19, 2009.
  • Big plans on campus. Business Week, Fall 2004. Available from: http://www.businessweek.com/magazine/content/04_44/b3906650.htm Accessed November 19, 2009.
  • Minimum wage laws in the states. United States Department of Labor’s Wage and Hour Division (WHD), July 24, 2009. Available from: http://www.dol.gov/esa/minwage/america.htm#Texas Accessed August 31, 2009.
  • MatherRKarenchakLMRomanowskiEGKowalskiRPFourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibioticsAm J Ophthalmol2002133446346611931779